The 'Week in Review' - 21 April

This is a preview of subscriber content

Subscribe now to continue reading.

Culture and capability have been the focus this week. Will new leadership lead to change? Pre-Budget announcements are now coming 'thick and fast' but what else might we expect? We respond to questions from the audience about 'secrecy' and why the absence of celebrations about the 75th anniversary of the creation of the PBS? …

Subscribe now to continue reading.

The 'Week in Review' - 21 April

This is a preview of subscriber content

Latest Video

Most Read

Opportunity #1 - biosimilar policy failure has become impossible to ignore

Has any patient ever said they accept a rejection because of the Kaplan-Meier curve?

OncoSil secures FDA approval for targeted bile duct cancer device

Dimerix takes control of US development pathway for new kidney injury treatment

Pharmac aims to pivot toward faster process and broader value framework

New Stories

Novo Nordisk backs care for rural health professionals in southern NSW

Opportunity #3 - finally deliver on the repeated claims of patient-centricity

Departmental restructure formally splits medicines financing from pharmacy services

Wesfarmers Health evolves its loyalty program with new Pulse Rewards

CSL absorbs loss in reset year as investors back its plasma-led recovery

Opportunity #2 - AI can democratise HTA and the negotiations must not squander it

Opportunity #1 - biosimilar policy failure has become impossible to ignore

Sign In

The 'Week in Review' - 21 April

This is a preview of subscriber content

Latest Video

Most Read

Opportunity #1 - biosimilar policy failure has become impossible to ignore

Has any patient ever said they accept a rejection because of the Kaplan-Meier curve?

OncoSil secures FDA approval for targeted bile duct cancer device

Dimerix takes control of US development pathway for new kidney injury treatment

Pharmac aims to pivot toward faster process and broader value framework

Follow Us

New Stories

Novo Nordisk backs care for rural health professionals in southern NSW

Opportunity #3 - finally deliver on the repeated claims of patient-centricity

Departmental restructure formally splits medicines financing from pharmacy services

Wesfarmers Health evolves its loyalty program with new Pulse Rewards

CSL absorbs loss in reset year as investors back its plasma-led recovery

Opportunity #2 - AI can democratise HTA and the negotiations must not squander it

Opportunity #1 - biosimilar policy failure has become impossible to ignore